Novartis to acquire Avidity Biosciences for approximately $12 billion
October 27, 2025
Source: drugdu
76
Novartis agreed to acquire Avidity Biosciences for approximately $12 billion, or $72 per share.
The acquisition will help Novartis expand its rare disease treatment pipeline, particularly for muscle diseases.
Avidity Biosciences will spin out its early-stage heart disease treatment program into a new company called Spinco, which is expected to go public.
Avidity Biosciences, whose flagship drug Del-zota is in early-to-mid-stage clinical trials for Duchenne muscular dystrophy, also has other drug candidates for severe muscle diseases. The acquisition fits with Novartis' recent strategy of addressing patent cliffs on some of its blockbuster drugs through a series of deals.
Source：https://finance.eastmoney.com/a/202510273544630680.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
